Impact of a Patient Support Program on Patient Beliefs About Neovascular Age-Related Macular Degeneration and Persistence to Anti-Vascular Endothelial Growth Factor Therapy

This published study compares treatment persistence between patients prescribed intravitreal aflibercept (IVT-AFL) for neovascular age-related macular degeneration (nAMD) in Australia who enrolled on the patient support program (PSP) designed and delivered by Atlantis Health with persistence in a 10% sample of patients from the Australian Pharmaceutical Benefits Scheme (PBS) dataset. Patients in the PSP showed 88% persistence after two years on treatment as compared to 64% persistence after two years in the PBS sample. PSP patients also showed improved beliefs about nAMD disease and its treatment over the course of the program.